# A Clinical Study of MK0991 (Caspofungin) in Japanese Patients With Deep-seated Candida or Aspergillus Infections (0991-062)(COMPLETED)

> **NCT00717860** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 121 (actual)

## Conditions studied

- Fungal Infection

## Interventions

- **DRUG:** caspofungin acetate
- **DRUG:** Comparator: Micafungin sodium

## Key facts

- **NCT ID:** NCT00717860
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2017-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00717860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00717860, "A Clinical Study of MK0991 (Caspofungin) in Japanese Patients With Deep-seated Candida or Aspergillus Infections (0991-062)(COMPLETED)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00717860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*